Premium
Platinum (IV) Derivatives with Cinnamate Axial Ligands as Potent Agents Against Both Differentiated and Tumorigenic Cancer Stem Rhabdomyosarcoma Cells
Author(s) -
Zajac Juraj,
Novohradsky Vojtech,
Markova Lenka,
Brabec Viktor,
Kasparkova Jana
Publication year - 2020
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201913996
Subject(s) - cancer stem cell , rhabdomyosarcoma , prodrug , cancer research , cancer cell , chemistry , cancer , stem cell , biochemistry , microbiology and biotechnology , biology , medicine , sarcoma , genetics , pathology
Abstract To design an anticancer drug capable of inhibiting not only the proliferation of the differentiated tumor cells but also reducing the tumorigenic capability of cancer stem cells (CSCs), the new Pt IV prodrugs with axial cinnamate ligands were synthesized. We demonstrate their superior antiproliferative activity in monolayer and 3D spheroid antiproliferative activity tests using panel of cancer cell lines. An outstanding activity was found against rhabdomyosarcoma cells, one of the most problematic and poorly treatable pediatric tumors. The results also suggest that the released Pt II compound inhibits antiproliferative activity of cancer cells by DNA‐damage mediated mechanism; the released cinnamic acid can trigger processes leading to differentiation, making the CSCs more sensitive to killing by the platinum part of the complex. Pt IV complex with axial cinnamate ligands is the first Pt IV prodrug capable of overcoming CSCs resistance and induce death in both CSCs and bulk cancer.